我们的博客

Medtronic's FDA approval for asleep deep brain stimulation (DBS) surgery provides patients with a new treatment option, offering comfort, safety, and comparable results to awake DBS.

Our recently published study in the Journal of Neurology showed that medication dosage was reduced by an average of 32% within the first year after DBS, and remained stable at a reduced dose for 10 years. The types of medication taken could also be simplified.

A study published in the scientific journal Neurology in July 2020, showed that early deep brain stimulation (DBS) is safe and has benefit over standard medical therapy. Early DBS may reduce the risk of Parkinson disease progression.